Patents are currently in place that prevent companies from making a generic version of Bethkis. After the first patent expires in September 2022, however, this situation may change. Although tobramycin is often referred to as the "generic name" for Bethkis, it is simply the active ingredient in this product and not a generic version of it.
Bethkis® (tobramycin inhalation solution) is a prescription medication used to treat people with cystic fibrosis who have a certain bacterial infection. It belongs to a group of medicines known as aminoglycoside antibiotics.
Bethkis is made by Catalent Pharma Solutions, LLC, for Cornerstone Therapeutics, Inc. It is protected by patents that prevent any generic Bethkis from being manufactured in the United States.
The first patent for Bethkis is set to expire in September 2022. This is the earliest predictable date that a generic version could become available.
However, other circumstances could come up to delay or shorten this exclusivity period. This includes such things as lawsuits or other patents for new Bethkis uses. Once the patents expire, there may be several companies that manufacture a generic Bethkis drug.
No -- tobramycin is the active ingredient in Bethkis, not a generic version of it. What can be confusing is that the active ingredient of a drug is often referred to as the "generic name."
The generic name is different from a generic version of a medicine. In order for there to be a generic version, the original medicine must have gone off-patent and another company besides the original manufacturer must make the product.